Moxonitex pills 400mcg, 28pcs

Composition

of 1 tab. Moxonidine 400 mcgm Auxiliary substances: lactose monohydrate, povidone K 25, crospovidone, magnesium stearate. Composition of the film shell: opadray Y-1-7000 (titanium dioxide, hypromellose, macrogol 400), iron oxide red dye.

Pharmacological action

Selective agonist of imidazoline receptors. It is responsible for reflex control of the sympathetic nervous system (receptors are localized in the ventro-lateral part of the medulla oblongata). It is slightly bound to central α2-adrenergic receptors, reduces systolic and diastolic blood pressure with a single and long-term use. With prolonged use, it reduces left ventricular myocardial hypertrophy, eliminates signs of myocardial fibrosis, microarteriopathy, normalizes capillary blood supply to the myocardium, reduces OPSS, pulmonary vascular resistance, while cardiac output and heart rate do not change significantly. During treatment, the activity of norepinephrine and epinephrine, renin, angiotensin II at rest and during exercise, atrial natriuretic peptide (during exercise) and plasma aldosterone decreases. Reduces tissue resistance to insulin by 21% compared to placebo in obese patients and insulin-resistant patients with moderate arterial hypertension, stimulates the release of growth hormone. It does not affect the metabolism of glucose and lipids. Duration of action – more than 12 hours.

Indications

Arterial hypertension.

Use during pregnancy and lactation

No reliable studies of the use of moxonidine in pregnant women have been conducted. Animal studies have shown an embryotoxic effect. There are no clinical data on the negative effect on the course of pregnancy. However, Moxonitex should only be used in pregnant women if the intended benefit to the mother outweighs the potential risk to the fetus. Moxonidine is excreted in breast milk, and women are advised to stop breastfeeding or discontinue the drug during treatment.

Recommendations for use

Moxonitex is prescribed orally, regardless of food intake, with a sufficient amount of liquid. The dosage regimen is selected individually. The initial dose is 200 mcg in the morning. If the therapeutic effect is insufficient, the dose is increased to 400 mcg/day once or in 2 doses after 3 weeks. The maximum daily dose is 600 mcg, the maximum single dose is 400 mcg. In patients with moderate renal impairment (creatinine clearance 30-60 ml / min), a single dose should not exceed 200 mcg, the maximum daily dose is 400 mcg.

Contraindications

-Hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption; – severe cardiac arrhythmias (severe bradycardia (less than 50 beats / min at rest), sinus node weakness syndrome or sinoatrial block, AV block II and III degrees);- chronic heart failure (NYHA FC III-IV);— severe renal insufficiency (creatinine clearance <30 ml / min, serum creatinine concentration >160 mmol / l) and hemodialysis; – concomitant use with tricyclic antidepressants;— under 18 years of age;— breast-feeding period— – hypersensitivity to moxonidine or any other component of the drug. The drug should be used with caution in patients with grade I AV block (risk of developing bradycardia), coronary artery diseases (including CHD, unstable angina, early post-infarction period), peripheral circulatory diseases (including intermittent claudication, Raynaud’s syndrome), epilepsy, Parkinson’s disease, depression, glaucoma, moderate renal failure (creatinine clearance 30-60 ml/min, serum creatinine 105-160 mmol/min l), liver failure, pregnancy.

Side effects

According to WHO, side effects are classified according to their frequency as follows: common (>1/100, ><1/10), uncommon (>1/1000, <1/10), uncommon (><1/100), rare (>1/10 000, <1/100), rare (><1/1000) and very rare (From the cardiovascular system: infrequently-bradycardia, marked decrease in blood pressure (including orthostatic hypotension). From the central nervous system: often – dizziness (vertigo), headache, drowsiness, insomnia; infrequently – fainting, increased excitability. From the side of the organ of hearing and labyrinth disorders: infrequently-tinnitus. From the digestive system: very often – dryness of the oral mucosa; often-diarrhea, nausea, vomiting, dyspepsia. From the skin and subcutaneous tissues: often-skin pruritus, skin rash; infrequently-angioedema (angioedema). From the musculoskeletal system: often-back pain; infrequently-pain in the neck. General disorders and disorders at the injection site: often-asthenia; infrequently-peripheral edema.

Interaction

The combined use of moxonidine in other antihypertensive agents leads to an additive effect. Tricyclic antidepressants may reduce the effectiveness of central antihypertensive agents, and therefore their combined use with moxonidine is not recommended. Moxonidine may enhance the sedative effects of tricyclic antidepressants, tranquilizers, ethanol, sedatives, and sleeping pills. Moxonidine is able to moderately improve impaired cognitive function in patients receiving lorazepam. Moxonidine may increase the sedative effect of benzodiazepine derivatives when used concomitantly. Moxonidine is excreted by tubular secretion, so its interaction with other drugs excreted by tubular secretion is not excluded.

Overdose

Symptoms: headache, marked decrease in blood pressure, bradycardia, palpitations, weakness, drowsiness, dryness of the oral mucosa; rarely-vomiting and epigastric pain. Paradoxical arterial hypertension and hyperglycemia are potentially possible. Treatment: symptomatic. There is no specific antidote. With a pronounced decrease in blood pressure, it is recommended to restore the BCC by introducing fluid. Alpha-adrenergic antagonists can reduce or eliminate transient arterial hypertension in the case of an overdose of moxonidine.

Special instructions

During treatment, regular monitoring of blood pressure, heart rate and ECG is required. If it is necessary to cancel the simultaneous use of beta-blockers and Moxonitex, the beta-blockers are first canceled and only a few days later – Moxonitex. Currently, there is no evidence that discontinuation of Moxonitex® leads to an increase in blood pressure. However, do not abruptly stop using Moxonitex. Elderly patients may have an increased risk of developing cardiovascular complications due to the use of antihypertensive drugs, so therapy with Moxonitex should be started with a minimum dose. The effect of Moxonitex on the ability to drive vehicles or operate machinery has not been studied. Taking into account the possible occurrence of dizziness and drowsiness, patients should exercise caution when engaging in potentially dangerous activities, such as driving vehicles or operating equipment that require increased concentration of attention.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C

Shelf life

2 years

Active ingredient

Moxonidine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For pregnant women as prescribed by a doctor, For adults as prescribed by a doctor

Indications

Hypertension